


Improving Women's Healthcare

osom[®]
B V B L U E[®] **T E S T**

Bacterial Vaginosis can contribute to preterm births, which costs the U.S. healthcare system more than \$26 billion annually and affects 1-in-8 newborns every year.^{1,10}



Bacterial Vaginosis

Bacterial vaginosis is the most common cause of vaginal symptoms among women of childbearing age, accounting for 40-50 percent of cases.¹⁰ The prevalence in the U.S. is estimated to be 29% among women 14-49 years old and 51% in African-American women.²

The causative agents of the infection are bacterial pathogens such as *Gardnerella vaginalis*, *Bacteroides*, *Prevotella* and *Mobiluncus*. These pathogens produce an enzyme called sialidase which has been associated with an increased risk of pre-term birth.⁴

If left untreated bacterial vaginosis can lead to complications such as:

- Susceptibility to HIV and other STD's (HSV, chlamydia and gonorrhea)
- Postoperative infection after vaginal or pelvic surgery (hysterectomy or abortion)
- Increased risk of preterm delivery in pregnant women
- Endometriosis
- Upper genital tract infections such as pelvic inflammatory disease³

WHAT THE EXPERTS ARE SAYING

"[A] potential one-half reduction of such adverse outcomes among women who are BV-positive could have an impact in reducing overall miscarriage and preterm birth rates, which were not reduced in the last decade..."⁴

"Integrating a simple infection screening programme into routine antenatal care leads to a significant reduction in preterm births and reduces the rate of late miscarriage in a general population of pregnant women."⁵

"Elevated sialidase level that is measured at 12 weeks of gestation is associated strongly with early spontaneous preterm births and miscarriage... as the amount of vaginal sialidase activity increased, the likelihood of adverse outcome also increased."⁴

DIAGNOSTIC CHALLENGES

There are a number of diagnostic options available. However, choices may have to be made in terms of:



ACCURACY

Patient receives correct diagnosis


















TIME

Patient receives correct diagnosis in a timely manner



COST

Diagnosis is obtained cost-effectively and affordably

METHOD	FEATURES			
AMSEL CRITERIA	<ul style="list-style-type: none"> Requires the assessment of 4 different tests/criteria. If three of these four criteria are present, a diagnosis of BV can be made: <ul style="list-style-type: none"> Presence of a thin gray/white vaginal discharge Vaginal pH > 4.5 Positive whiff test (amines) Presence of > 20% clue cells on a wet mount Requires a microscope and training 			
GRAM STAIN WITH NUGENT'S SCORING	<ul style="list-style-type: none"> A multistep procedure in which a stained vaginal smear is examined microscopically Bacteria are quantified and scored, with a score of ≥ 7 considered positive for BV Accurate; generally considered the gold standard Labor intensive; requires advanced skills 			
DNA PROBE	<ul style="list-style-type: none"> Accurate Expensive Not CLIA waived Does not allow for test and treat approach Over-diagnosis is possible⁹ 			
POINT-OF-CARE OSOM[®] BVBLUE[®] TEST	<ul style="list-style-type: none"> Good sensitivity vs. Gram Stain CLIA waived; easy-to-read, objective results in 10 minutes No equipment or specialized training required Actionable, diagnostic result; test-and-treat patient in one visit 			

WHY IS A POINT-OF-CARE TEST IMPORTANT? "The majority of women at the greatest risk for the sequelae of BV are not in settings where the conventional diagnostic methods are either practical or possible, and they would greatly benefit from access to rapid and reliable point-of-care tests to improve the diagnosis and management of BV."⁶

OSOM® BVBLUE® Procedure

- Detects elevated activity of vaginal fluid sialidase associated with 4 pathogens
- 92.8% sensitive and 98% specific vs. gram stain



Product not available in all markets.

ORDER	CONFIGURATION	CATALOG #
<input type="radio"/> OSOM® BVBLUE® RAPID TEST KIT	25 TESTS	183
<input type="radio"/> OSOM® BVBLUE® CONTROL KIT	---	184
<input type="radio"/> OSOM® VAGINITIS SWAB TRANSPORT SYSTEM	50 SWAB SETS	185

The ability of the OSOM® BVBLUE® Test to accurately, quickly and cost effectively detect BV offers significant benefits to the patient and clinician alike:

- Begin immediate and proper treatment
- Provide opportunity for appropriate health education during the visit
- Help prevent recurrence and reduce associated health risks
- The performance of OSOM® BVBLUE® was better than the methods based on Amsel's Criteria (97.6% vs 67.1%).⁷
- "BVBLUE® is a useful point-of-care diagnostic tool to provide a presumptive diagnosis of BV, especially in situations where microscopic capabilities are unavailable."⁸

REFERENCES

1. Preterm Birth. CDC. Mar 23, 2012. www.cdc.gov/reproductivehealth/maternalinfanthealth/preterm-birth.htm
2. Koumans EH, Sternberg M, Bruce C, et al.: The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. Nov 2007;34(11):864-9.
3. Ness, Roberta B., Kip, Kevin E., Sharon L. Hillier et al.: A Cluster Analysis of Bacterial Vaginosis-associated Microflora and Pelvic Inflammatory Disease. Am J Epidemiol. 2005;162:585-590.
4. Cauci, Sabina PhD, Flatau Cuihan, Jennifer, PhD, MPH: High Sialidase Levels Increase Preterm Birth Risk Among Women Who Are Bacterial Vaginosis-Positive in Early Gestation. Amer Jml OB&GYN, February 2011;142.e1-142.e9
5. Kiss, Herbert, Petricevic, Ljubomir and Peter Husslein: Prospective Randomized Controlled Trial of an Infection Screening Programme to Reduce the Rate of Preterm Delivery. BMJ, doi:10.1136/bmj.3869.519653.EB; August 4, 2004
6. Bradshaw, C.S., Morton, A.N., Garland, S.M. et al.: Evaluation of a Point-of-Care Test, BVBLUE®, and Clinical Laboratory Criteria for Diagnosis of Bacterial Vaginosis. Jml, of Clin. Microbiology, Mar. 2005;43(3):1304-1308
7. Shujatullah, Fatima, Khan, Haris M., Khatoun, Razia, et al: An Evaluation of OSOM® BVBLUE® Test in the Diagnosis of Bacterial Vaginosis. Asian Pacific Jml of Trop Med. 2010;574-576
8. Myzluk, L., Romanowski, B. and S. Johnson: BVBLUE® Test for Diagnosis of Bacterial Vaginosis. Jml, of Clin. Microbiology, May 2003;41(5):1925-1928
9. Sobel, Jack M.D., Barbieri, Robert L. M.D., and Vanessa Barris, M.D.: Bacterial Vaginosis. UpToDate, www.uptodate.com, 2012
10. Chowdhury MMH. Gardnerella vaginalis-associated vaginitis: a review. Trop Geogr Med 1986; 138: 113-125

BVBLUE® is a registered trademark of Gryphus Diagnostics, LLC.
OSOM® and the OSOM Training logo are registered U.S. trademarks of Sekisui Diagnostics, LLC.

©2013 Sekisui Diagnostics, LLC. All rights reserved.



SEKISUI
DIAGNOSTICS

osom

THE AMERICAS

Sekisui Diagnostics, LLC
4 Hartwell Place
Lexington, MA 02421
Phone: 800 332 1042
Fax: 800 762 6311
Email: osomrapidtests@sekisui-dx.com
ISO 13485:2003 Certified

INTERNATIONAL

Sekisui Diagnostics (UK) Limited
50 Gibson Drive
Kings Hill, West Malling, Kent, ME19 4AF, UK
Phone: +44 (0) 1732 220022
Fax: +44 (0) 1732 220024
Email: info@sekisui-dx.com
ISO 9001:2000 Certified, ISO 13485:2003 Certified

www.osomtests.com



1409-D, 03/13